Transcript RCGP training certificate on hepatitis C

PHE London / RCGP training
online: New HCV Training in
Short Bites
Emma Burke, PHE London Alcohol and Drug Programme Manager
& Danny Morris, Expert Lead RCGP Hepatitis B&C Part 1
The scale of the problem
2
•
Estimated 214,000 in the UK have Hepatitis C
•
Injecting drug use continues to be the most important risk factor for infection
•
50% of people who have ever injected are expected to be infected
•
Rates are on the increase in IPED injectors
•
40% of cases are estimated to be undiagnosed
•
Left untackled HCV will lead to great health costs – both financial and to the
individual
•
There is no vaccine, but there is a cure
•
Only 3% of those with the virus are estimated to be treated in any one year
•
Treating people for HCV leads to a range of improved outcomes
Figure 1: Trend in anti-HCV prevalence* among people who inject drugs in England: 2003-2013
*During 2009 to 2011 there was a phased change in the sample collected in the survey from an oral fluid to dried blood spot
(DBS). The sensitivity of the anti-HCV tests on these two sample types is different. The sensitivity of the oral fluid test for antiHCV is approximately 92%,(28) that on DBS samples is close to 100%. Data presented here have been adjusted for the
sensitivity of the oral fluid test.
3
Hepatitis C in the UK 2014 report
What needs to be done?
4
•
Continued and improved testing rates of drug users (18.9% of eligible
clients in the system have no record of a HCV test and 25.4% of those new
to treatment)
•
Retest those who have been in the system for some time who have
continued risk factors
•
Continued harm reduction advice
•
Embedding testing in any new contracts which are under development
•
Develop pathways from drug treatment into HCV treatment, if pathways are
not already in place (good examples are already in place across a range of
London boroughs)
•
Decisions to be made about future access to new HCV drugs
Why should we do it?
5
•
Increasing testing leads to greater awareness of the disease, enabling
people to make better decisions about their health – e.g. continued alcohol
consumption
•
Testing offers the opportunity to provide appropriate harm reduction advice
to those who test positive which will reduce the further spread of infection
•
Those who test positive have the opportunity to access treatment,
potentially leading to a cure
•
Curing those with HCV leads to reduced prevalence in the drug using
population and reduces the further spread of infection
•
Currently the prevalence of HCV is increasing
RCGP training online: new
training in short bites
Danny Morris, Expert Lead RCGP Hepatitis B and C Part 1
Developing competence through education
Certificate in Detection,
Diagnosis and Management of
Hepatitis B and C in Primary
Care
(Part 1)
Online learning and f2f
NICE public health guidance
Identified a range of social and cultural
barriers to hepatitis C testing
Lack of awareness among
health and social care
professionals about the
condition and of populations at
increased risk and that and this
may contribute to a low
uptake of testing
Repurposing e-learning
• Designed to specifically meet
learning needs of the range of nonclinical workers
• Online Learning Environment (OLE)
is RCGP’s flagship platform for
delivering online educational courses
• GPs and other healthcare
professionals have increasingly
adopted online learning as a
preferred way of accessing
education
Development
• Developed by RCGP e-learning team and hosted on the
OLE platform
• Content will be jointly badged PHE
• Content and structure scoped as part of the development
process, around identified objectives
• Materials developed by educational and clinical
professionals under the guidance of the RCGP e-learning
team, including a range of substance misuse
professionals and service users
Non- clinical or medical professionals
providing health and social care services
The
audience
for people at increased risk of hepatitis C
Non-clinical
primary
and secondary
infectionstaff
andinalso
to people
who care
currently
including, health visitors, midwives, healthcare
orassistants
formerly
inject workers
drugs,astheir
and support
well aspeers,
staff in sexual
health, genitourinary
and HIV clinics
including
those inmedicine
recovery
People working in drugs services including volunteers
and service user advocates and peer educators
Staff in community-based criminal justice services
Prison and youth offender staff
Drug user peer, carer and recovery networks
• an introduction
to includes
hepatitis C virus, prevalence
Course
content
and epidemiology
• the impact and public health burden
• transmission and prevention
• testing procedures and diagnosis
• management and treatment
Clearly defined objectives, educational material,
and self-assessments to facilitate engagement and
reflection
* Pre
course assessment
Session
1 * Pre course assessment
Session 1: Understanding
Hepatitis C
This session provides an
understanding of hepatitis C
and its prevalence
It also gives an overview of
the liver, its function and
and natural history of
untreated hepatitis C liver
disease
Session
2
Session 2: Preventing
Hepatitis C Transmission
This session will provide participants with core information on HCV
transmission routes and risk prevention strategies
Session 3
Session 3: Testing and
Diagnosis
This session will introduce
participants to the main
tests used to identify
exposure to hepatitis C,
whether a person is actively
infected and to assess and
monitor liver health
Session 4
Session 4: Treatment and care
This session will summarise current hepatitis C (HCV) treatment options,
factors that influence treatment effectiveness and potential future
treatment opportunities
RCGP’s Online Learning Environment
www.elearning.rcgp.org.uk
Course Name?
21
•
Improving identification of Hepatitis C in health and Social Care settings
•
Understanding Hepatitis C in Health and Social Care
•
Managing Hepatitis C from Diagnosis to Treatment and Care
Presentation title - edit in Header and Footer